<?xml version="1.0" encoding="utf-8" ?>
<INTERACTIONS>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ACETAZOLAMIDE" rxcui="167">
<ATC code="S01EC01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the undesirable effects, and especially of metabolic acidosis, of the acetylsalicylic acid in large doses and of the acetazolamide, due to decrease of the elimination of the acetylsalicylic acid by the acetazolamide</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="ANAGRELIDE" rxcui="596724">
<ATC code="L01XX35" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of hemorrhagic events 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN II RECEPTOR ANTAGONISTS or ANGIOTENSIN RECEPTOR BLOCKERS (ARBs)" code="C09CA0-001" /></DRUG2>
<DESCRIPTION>For anti-inflammatory dosages of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500mg by dose and/or &lt;3g per day):

Acute renal insufficiency with dehydrated patients, due to decrease of the glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect. </DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the beginning of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ORAL ANTICOAGULANTS " code="B01A-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage, especially in cases with a previous gastro duodenal ulcer. 

</DESCRIPTION>
<SEVERITY>Contraindication with:</SEVERITY>
<COMMENT>- anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >= 3g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="NON STEROIDAL ANTI-INFLAMMATORY DRUGS" code="M01A-002" /></DRUG2>
<DESCRIPTION>Increase of the risk of digestive system ulceration and hemorrhage.</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="CLOPIDOGREL" rxcui="32968">
<ATC code="B01AC04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet aggregation activities. 

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-except in validated indications for this combination of drugs in acute coronary syndromes. </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="DEFERASIROX" rxcui="614373">
<ATC code="V03AC03" />
</DRUG>
</DRUG2>
<DESCRIPTION>With anti-inflammatory doses of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 g per day):

increase of the risk of digestive ulceration and hemorrhage</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="DIURETICS" code="C0E-001" /></DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 g per day):

Acute renal insufficiency in dehydrated patients, due to decrease of the glomerular filtration as a result of a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="GLUCOCORTICODS (EXCEPT FOR HYDROCORTISONE) " code="A0-H0-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1 g per dose and/or >3 g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (CURATIVE DOSES AND/OR OLDER PATIENT)" code="B01AB-001" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="LOW MOLECULAR WEIGHT HEPARINS AND RELATED DRUGS (PREVENTIVE DOSES) " code="B01AB-002" /></DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding heparin in preventive doses to acetylsalicylic acid, whatever the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring.</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="UNFRACTIONATED HEPARIN (CURATIVE DOSES AND/OR OLDER PATIENTS)" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage (inhibition of the platelet function and irritation of the gastro duodenal mucosa by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>Not recommended </SEVERITY>
<COMMENT>-with anti-inflammatory doses of acetylsalicylic acid (>=1g per dose and/or >=3 g per day)</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="UNFRACTIONATED HEPARIN (PREVENTIVE DOSES)" rxcui="">
</DRUG>
</DRUG2>
<DESCRIPTION>The combination of medications acting at different levels of hemostasis increases the risk of bleeding. Thus, with patients under the age of 65, adding preventive doses of heparin or similar substances to acetylsalicylic acid, regardless of the dosage, must be taken into account by maintaining clinical monitoring and possibly biological monitoring </DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="ANGIOTENSIN CONVERTING ENZYME INHIBITORS (ACE INHIBITORS)" code="C09AA" /></DRUG2>
<DESCRIPTION>For anti-inflammatory doses of acetylsalicylic acid (&gt;=1g per dose and/or &gt;=3g per day) or for analgesic or antipyretic doses (&gt;=500 mg per dose and/or &lt;3 g per day):

Acute renal insufficiency in dehydrated patients, due to decreased glomerular filtration following a decrease of the synthesis of the renal prostaglandins. Furthermore, reduction of the antihypertensive effect.</DESCRIPTION>
<SEVERITY>Precaution for use</SEVERITY>
<COMMENT>Hydrate the patient and monitor renal function at the start of treatment.</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)" code="N06AB" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage 

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="METHOTREXATE" rxcui="6851">
<ATC code="L01BA01" />
<ATC code="L04AX03" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the toxicity, especially hematological, of the methotrexate (decrease of its renal clearance by the acetylsalicylic acid)</DESCRIPTION>
<SEVERITY>With doses of methotrexate > 20 mg/week</SEVERITY>
<COMMENT>-Contraindication </COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PEMETREXED" rxcui="68446">
<ATC code="L01BA04" />
</DRUG>
</DRUG2>
<DESCRIPTION>Risk of increase of the toxicity of the pemetrexed (decrease of its renal clearance by the acetylsalicylic acid in anti-inflammatory doses).</DESCRIPTION>
<SEVERITY>Not Recommended</SEVERITY>
<COMMENT>-in case of weak to moderate renal function</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="PROBENECID" rxcui="8698">
<ATC code="M04AB01" />
</DRUG>
</DRUG2>
<DESCRIPTION>Decrease of the uricosuric effect due to competition of the elimination of the uric acid at the level of the renal tubules</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<CLASS name="THROMBOLYTICS" code="B01AD" /></DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage

</DESCRIPTION>
<SEVERITY>Take into account</SEVERITY>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICAGRELOR" rxcui="1116632">
<ATC code="B01AC24" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>--except for validated indications for this combination in acute coronary syndromes</COMMENT>
</INTERACTION>
<INTERACTION>
<SOURCE>
<CLINICAL_SOURCE>ANSM</CLINICAL_SOURCE>
<SOURCE_FILE>5-ACETYLSALICYLIC-ACID.html
</SOURCE_FILE>
</SOURCE>
<DRUG1>
<DRUG name="ACETYLSALICYLIC ACID" rxcui="1191">
<ATC code="A01AD05" />
<ATC code="B01AC06" />
<ATC code="N02BA01" />
</DRUG>
</DRUG1>
<DRUG2>
<DRUG name="TICLOPIDINE" rxcui="10594">
<ATC code="B01AC05" />
</DRUG>
</DRUG2>
<DESCRIPTION>Increase of the risk of hemorrhage due to addition of the platelet antiagregation actions

</DESCRIPTION>
<SEVERITY>Not recommended</SEVERITY>
<COMMENT>If administering the substances together cannot be avoided, strict clinical monitoring.</COMMENT>
</INTERACTION>
</INTERACTIONS>
